Windtree Announces Craig Fraser Plans To Retire From His Role As Chief Executive Officer, Effective December 1, 2024, Will Remain On The Board Of Directors Of The Company As Chairman; Board Has Appointed Jed Latkin, A Current Director Of The Company, To Replace Mr. Fraser As CEO

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board.